<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01793038</url>
  </required_header>
  <id_info>
    <org_study_id>Mific-3</org_study_id>
    <nct_id>NCT01793038</nct_id>
  </id_info>
  <brief_title>Clomiphene Citrate Plus uFSH Versus Aromatase Inhibitor Plus uFSH in Clomiphene Resistant Infertile PCOS Women</brief_title>
  <official_title>Clomiphene Citrate Plus HPuFSH Versus Letrozole Plus HPuFSH in Clomid Resistant Infertile PCOS Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura Integrated Fertility Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura Integrated Fertility Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polycystic ovarian syndrome (PCOS) is a condition characterized by infertility, infrequent
      periods and amenorrhea or irregular bleeding plus anovulatory infertility. Clomid is the
      standard first drug of treatment for ovulation induction. Ovulation and conception will occur
      in approximately 75 and 30 percent of cases respectively. Cases not ovulating in response to
      doses of clomid up to 150 mg/day are known as clomid resistant PCOS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To test whether CC co- treatment with chronic low dose HP uFSH versus lirizole plus chronic
      low dose HP uFSH in CC resistant PCOS will yield comparable results in terms of, ovulation
      rate, lower follicle number, lower HP uFSH dose, better outcome in terms of pregnancy rates,
      better cost-effectiveness ratio, lower multiple pregnancy rates, lower cycle cancellation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ovulation rate</measure>
    <time_frame>30 days</time_frame>
    <description>percentage of ovulatory cycles per started and per completed cycles</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>endometrial thickness</measure>
    <time_frame>4 weeks</time_frame>
    <description>endmetrial thickness at time of ovulation triggering</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ongoing cycle pregnancy rate</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>CC-plus uFSH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clomiphene citrate 50 mg tablets twice/day for cycle days 3-7 plus daily IM injection of 37.5 IU HP uFSH for days 3-12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aromataze inhibitor plus uFSH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aromataze inhibitor (litrezole )2.5 mg twice daily for cycle days 3-7 plus daily IM injection of uFSH 37.5 IU for cycle days 3-12</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aromatase inhibitor (litrezole) plus uFSH arm</intervention_name>
    <description>literozole tablets 5 mg /day for days 3-7 plus intramuscular injections of uFSH 37.5 IU/day for days 3-12</description>
    <arm_group_label>Aromataze inhibitor plus uFSH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clomiphene citrate-uFSH arm</intervention_name>
    <description>clomiphene citrate 50 mg tablets twice /day for 5 days plus 37.5 IU uFSH IM injections daily for 10 days</description>
    <arm_group_label>CC-plus uFSH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CC resistant PCOS

          -  Infertile

          -  Females

          -  Age 18-38

        Exclusion Criteria:

          -  Hyperprolactinaemia

          -  Cushing syndrome

          -  Adult onset adrenal hyperplasia

          -  Age &gt; 38

          -  Other infertility factors in the couple than PCOS: male factor,tubal
             factor,edometriosis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>mohamad E GHanem, MD</last_name>
    <phone>00201223366955</phone>
    <email>meghanem87@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mansoura Integrated fertility center</name>
      <address>
        <city>Mansoura</city>
        <state>Dekahlia</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamad E Ghanem, MD</last_name>
      <phone>00201223366955</phone>
      <email>meghanem87@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Mohamad E Ghanem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Abdellah MS. Reproductive outcome after letrozole versus laparoscopic ovarian drilling for clomiphene-resistant polycystic ovary syndrome. Int J Gynaecol Obstet. 2011 Jun;113(3):218-21. doi: 10.1016/j.ijgo.2010.11.026. Epub 2011 Apr 1.</citation>
    <PMID>21457973</PMID>
  </reference>
  <reference>
    <citation>Palomba S, Falbo A, Zullo F. Management strategies for ovulation induction in women with polycystic ovary syndrome and known clomifene citrate resistance. Curr Opin Obstet Gynecol. 2009 Dec;21(6):465-73. doi: 10.1097/GCO.0b013e328332d188. Review.</citation>
    <PMID>19809318</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2013</study_first_submitted>
  <study_first_submitted_qc>February 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2013</study_first_posted>
  <last_update_submitted>March 5, 2013</last_update_submitted>
  <last_update_submitted_qc>March 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura Integrated Fertility Center</investigator_affiliation>
    <investigator_full_name>Mohamad Elsaid Ghanem</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>PCOS</keyword>
  <keyword>clomiphene citrate resistant PCOS</keyword>
  <keyword>Aromatase inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

